The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples